Biotechnology · Nasdaq
VRTXVertex Pharmaceuticals Inc / Ma
- Last close
- $538.60 -0.7%
- 52-week range
- $412.27 to $568.67
- Market cap
- $137B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own 10 years
Below its 10-year median on 1 of 4 multiples
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- 34.7x
- Earnings yield
- 2.9%
- Price / sales
- 10.5x
- Price / book
- 6.5x
- Price / operating cash flow
- 37.0x
- EV / EBITDA
- 29.7x
- EV / sales
- 10.4x
- Free cash flow yield
- 2.3%
Profitability
- Gross margin
- 85.5%
- Operating margin
- 33.2%
- Net margin
- 30.7%
- Return on equity
- 19.0%
- Return on capital
- 14.2%
Growth per year
- Revenue, 3 years
- +10.4%
- Revenue, 5 years
- +14.1%
- Revenue, 9 years
- +24.2%
- EPS, 3 years
- +6.1%
Balance sheet
- Cash and investments
- $6.30B
- Total debt
- $4.50B
- Net cash
- $1.81B
- Debt / equity
- 0.22x
- Current ratio
- 2.34x
Shares and dividend
- Shares outstanding
- 254M
- Share count, 5 years
- -2.1%
- Beta, 1 year
- 0.43
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- n/a
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
Manufactured Product Other went from 14% to 7% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| TRIKAFTAKAFTRIO | $10.3B | 85.9% | +1% |
| ALYFTREK | $838M | 7.0% | n/a |
| Manufactured Product Other | $820M | 6.8% | +5% |
| CASGEVY | $116M | 1.0% | +1,058% |
| Collaborative and Royalty | $30.7M | 0.3% | n/a |
Biotechnology peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| ONC BeOne Medicines Ltd. | $619B | +33% | 17.8% | 689x | 93.6x | Not enough history |
| ABBV AbbVie Inc. | $521B | +11% | 32.2% | 50.8x | 7.9x | 72nd percentile |
| AMGN Amgen Inc | $252B | +8% | 32.4% | 27.0x | 6.5x | 78th percentile |
| GILD Gilead Sciences, Inc. | $208B | +7% | -7.6% | No earnings | 6.7x | No earnings |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137B | +10% | 33.2% | 34.7x | 10.5x | 71st percentile |
| MRNA Moderna, Inc. | $90.4B | +13% | -116% | No earnings | 35.8x | No earnings |
The company
- Sector
- Health Care
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani
- Founded
- 1989
- Headquarters
- Boston, MA
- Fiscal year ends
- December
- Website
- vrtx.com
What it does
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about VRTX.
Held by 1,446 active funds. Crowd level: crowd building, 3 rising quarters.
Open the Smart money tab